CF Foundation Awards $3.5M to Develop Antibiotic ACG-701

The Cystic Fibrosis Foundation has awarded up to $3.5 million to Aceragen to support the clinical development of ACG-701, an investigational antibiotic to treat pulmonary exacerbations in people with cystic fibrosis (CF).

Startup Spotlight: Two Raleigh biopharma firms join forces in search for potential therapies

RESEARCH TRIANGLE PARK – Raleigh-based Aceragen, a biopharmaceutical company developing therapeutics for rare and orphan diseases, has acquired Arrevus, another Raleigh company with a similar focus.